TransThera Sciences (Nanjing), Inc. (HKG:2617)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
70.55
-5.25 (-6.93%)
Sep 9, 2025, 4:08 PM HKT
-6.93%
Market Cap28.00B
Revenue (ttm)n/a
Net Income (ttm)-434.19M
Shares Out396.90M
EPS (ttm)-1.14
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume690,500
Average Volume419,722
Open75.80
Previous Close75.80
Day's Range70.20 - 78.70
52-Week Range20.20 - 78.90
Betan/a
RSI76.03
Earnings DateAug 25, 2025

About HKG:2617

TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 121
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2617
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.